Asia-Pacific Multiple Myeloma Therapeutics Markets to 2021 - APAC Market Is Projected to Expand at a CAGR of 7.40% During the Period from 2015 to 2021
The research report titled "Multiple Myeloma Therapeutics in Asia-Pacific Markets to 2021 - Growth Driven by Rising Prevalence, Continued Success of Velcade, Revlimid and Emerging Supplementary Treatments", and it states that the overall value of the Asia Pacific market for multiple myeloma therapeutics stood at US$1.7 bn in 2014.
View full press release